$1.88
+0.08
(+4.44%)▲
Insights on Adagene Inc-adr
In the last 1 year, Seagen, Inc. has given 76.6% return, outperforming this stock by 37.3%
5.32%
Downside
Day's Volatility :6.32%
Upside
1.05%
42.02%
Downside
52 Weeks Volatility :48.1%
Upside
10.48%
Period | Adagene Inc-adr | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 30.56% | -0.7% | 0.0% |
6 Months | 51.61% | 1.3% | 0.0% |
1 Year | 43.51% | -4.3% | -1.5% |
3 Years | -86.74% | 18.3% | -7.5% |
Market Capitalization | 70.8M |
Book Value | $1.89 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -0.86 |
Wall Street Target Price | 13.77 |
Profit Margin | -160.77% |
Operating Margin TTM | -29.19% |
Return On Assets TTM | -16.29% |
Return On Equity TTM | -37.28% |
Revenue TTM | 22.7M |
Revenue Per Share TTM | 0.52 |
Quarterly Revenue Growth YOY | 340.9% |
Gross Profit TTM | 10.2M |
EBITDA | -39.3M |
Diluted Eps TTM | -0.86 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.65 |
EPS Estimate Next Year | -2.33 |
EPS Estimate Current Quarter | -0.38 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 632.45%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 1.5M | - |
Net Income | -14.7M | - |
Net Profit Margin | -974.03% | - |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 480.0K | ↓ 68.24% |
Net Income | -17.3M | ↑ 17.49% |
Net Profit Margin | -3.6K% | ↓ 2628.86% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 480.0K | ↑ 0.0% |
Net Income | -16.4M | ↓ 4.96% |
Net Profit Margin | -3.4K% | ↑ 178.83% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 10.2M | ↑ 2019.85% |
Net Income | -73.2M | ↑ 345.24% |
Net Profit Margin | -719.18% | ↑ 2704.88% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 9.3M | ↓ 8.67% |
Net Income | -80.0M | ↑ 9.28% |
Net Profit Margin | -860.59% | ↓ 141.41% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 9.3M | - |
Net Income | -42.7M | - |
Net Profit Margin | -458.43% | - |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 8.4M | - |
Net Income | -51.1M | - |
Net Profit Margin | -607.32% | - |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 54.4M | - |
Total Liabilities | 95.4M | - |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 105.9M | ↑ 94.59% |
Total Liabilities | 162.9M | ↑ 70.68% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 84.3M | ↓ 20.42% |
Total Liabilities | 173.7M | ↑ 6.6% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 189.5M | ↑ 124.9% |
Total Liabilities | 33.0M | ↓ 81.02% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 152.4M | ↓ 19.58% |
Total Liabilities | 69.3M | ↑ 110.33% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 189.5M | ↑ 0.0% |
Total Liabilities | 33.0M | ↑ 0.0% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 178.6M | ↓ 5.78% |
Total Liabilities | 65.9M | ↑ 99.91% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 152.4M | - |
Total Liabilities | 69.3M | - |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 152.4M | ↑ 0.0% |
Total Liabilities | 69.3M | ↑ 0.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 135.3M | ↓ 11.22% |
Total Liabilities | 52.5M | ↓ 24.24% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -14.3M | - |
Investing Cash Flow | -29.5M | - |
Financing Cash Flow | 51.1M | - |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -18.2M | ↑ 27.26% |
Investing Cash Flow | 24.9M | ↓ 184.23% |
Financing Cash Flow | 69.7M | ↑ 36.5% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -28.5M | ↑ 57.16% |
Investing Cash Flow | 7.1M | ↓ 71.55% |
Financing Cash Flow | 4.4M | ↓ 93.63% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -43.4M | ↑ 52.17% |
Investing Cash Flow | -2.5M | ↓ 135.49% |
Financing Cash Flow | 145.4M | ↑ 3174.27% |
Q2 FY20 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -4.4M | ↑ 0.0% |
Investing Cash Flow | 3.9M | ↑ 0.0% |
Financing Cash Flow | 658.6K | ↑ 0.0% |
Q3 FY20 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -11.2M | ↑ 153.91% |
Investing Cash Flow | -335.7K | ↓ 108.64% |
Financing Cash Flow | 1.8M | ↑ 170.27% |
Q4 FY20 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -8.5M | ↓ 23.61% |
Investing Cash Flow | -360.9K | ↑ 7.49% |
Financing Cash Flow | 1.3M | ↓ 24.59% |
Sell
Neutral
Buy
Adagene Inc-adr is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Adagene Inc-adr | 38.24% | 51.61% | 43.51% | -86.74% | -86.74% |
![]() Moderna, Inc. | 14.4% | -34.97% | -51.36% | -48.82% | 345.97% |
![]() Regeneron Pharmaceuticals, Inc. | 5.45% | 11.42% | 13.15% | 75.11% | 123.61% |
![]() Novo Nordisk A/s | -4.11% | 21.75% | 48.89% | 177.94% | 327.61% |
![]() Seagen, Inc. | 2.71% | 11.07% | 66.1% | 14.54% | 259.34% |
![]() Vertex Pharmaceuticals Incorporated | -7.59% | 2.8% | 11.45% | 56.2% | 102.13% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Adagene Inc-adr | NA | NA | NA | -0.65 | -0.37 | -0.16 | 0.0 | 1.89 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -12.72 | -0.22 | -0.07 | 0.0 | 35.32 |
![]() Regeneron Pharmaceuticals, Inc. | 23.18 | 23.18 | 1.75 | 42.5 | 0.17 | 0.09 | 0.01 | 234.47 |
![]() Novo Nordisk A/s | 41.18 | 41.18 | 4.02 | 2.67 | 0.89 | 0.22 | 0.01 | 20.77 |
![]() Seagen, Inc. | NA | NA | 18.53 | -4.16 | -0.28 | -0.13 | 0.03 | 13.52 |
![]() Vertex Pharmaceuticals Incorporated | 26.38 | 26.38 | 0.5 | 15.04 | 0.23 | 0.14 | 0.0 | 64.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Adagene Inc-adr | Buy | $70.8M | -86.74% | NA | -160.77% |
![]() Moderna, Inc. | Buy | $30.4B | 345.97% | 24.73 | -38.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $88.5B | 123.61% | 23.18 | 30.47% |
![]() Novo Nordisk A/s | Buy | $459.0B | 327.61% | 41.18 | 35.11% |
![]() Seagen, Inc. | Hold | $40.2B | 259.34% | NA | -32.61% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $90.5B | 102.13% | 26.38 | 35.94% |
SC China Holding Ltd
FMR Inc
Artal Group S A
General Atlantic Llc
BosValen Asset Management Ltd
Morgan Stanley - Brokerage Accounts
Adagene Inc-adr’s price-to-earnings ratio stands at None
Read Moreadagene was co-founded by two serial entrepreneurs to power antibody discovery. its aim is to become the leading player in antibody discovery and engineering. it has developed a proprietary dynamic precision library (dpl) and is showcasing the power of the library with a unique pipeline of innovative antibody therapeutics that is advancing into clinical trials. adagene previously has raised three series of financing with over $86 million. investors include f-prime capital (formerly fidelity biosciences), eight roads ventures china (formerly fidelity growth partners asia), 6 dimensions capital, gp healthcare capital, sequoia china, and new world tmt. for more information, please visit www.adagene.com.
Organization | Adagene Inc-adr |
Employees | 248 |
CEO | Dr. Peter P. Luo Ph.D. |
Industry | Healthcare |